Schizophrenia 1 - Clinical (1)

[P149] Genome-wide DNA methylation risk scores for schizophrenia derived from blood and brain tissues further explain the genetic risk in patients stratified by polygenic risk scores for schizophrenia and bipolar disorder

*Kazutaka Ohi^1,2, Mihoko Shimada³, Midori Soda⁴, Daisuke Nishizawa⁵, Daisuke Fujikane¹, Kentaro Takai¹, Ayumi Kuramitsu¹, Yukimasa Muto¹, Shunsuke Sugiyama¹, Junko Hasegawa⁵, Kiyoyuki Kitaichi⁴, Kazutaka Ikeda⁵, Toshiki Shioiri¹ (1. Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan, 2. Department of General Internal Medicine, Kanazawa Medical University, Ishikawa, Japan, 3. Genome Medical Science Project (Toyama), National Center for Global Health and Medicine (NCGM), Tokyo, Japan, 4. Laboratory of Pharmaceutics, Department of Biomedical Pharmaceutics, Gifu Pharmaceutical University, Gifu, Japan, 5. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

Keywords:Epigenome-wide association study, methylation risk score, polygenic risk score, schizophrenia, bipolar disorder